ESTIV is proud to be one of the five partner organisations for the in3 project. The in3 project is funded by the EU’s Marie Sklodowska-Curie Action – Innovative Training Network (MSCA-ITN for short) that aims to drive the synergistic development and utilisation of in vitro and in silico tools for human chemical and nanomaterial (NM) safety assessment. The project has hired 15 PhD students, who are busy working on these aspects in 13 laboratories across Europe. The project is coordinated by Prof. Dr. Paul Jennings.
ESTIV will be involved in the prestigious European H2020 research project ONTOX which stands for “ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next-generation risk assessment”. ONTOX is aiming into the development of animal-free methods for testing chemical substances. ESTIV will be one of the major dissemination channels of the research activities. The ONTOX consortium consists of 18 European and American partners, and more than 60 scientists, many of them active members of ESTIV. The ONTOX project will kick off on 1 May 2021 for a period of 5 years and will be coordinated by Prof. Mathieu Vinken (Vrije Universiteit Brussel-Belgium), past-president of ESTIV.